Cargando…
Treatable Mechanisms in Asthma
Asthma is a heterogeneous condition, but firm identification of heterogeneity-focused treatments is still lacking. Dividing patients into subgroups of asthma pheno-/endotypes based on combined clinical and cellular biological characteristics and linking them to targeted treatments could be a potenti...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956930/ https://www.ncbi.nlm.nih.gov/pubmed/33570719 http://dx.doi.org/10.1007/s40291-021-00514-w |
_version_ | 1783664545133232128 |
---|---|
author | Cazzola, Mario Ora, Josuel Cavalli, Francesco Rogliani, Paola Matera, Maria Gabriella |
author_facet | Cazzola, Mario Ora, Josuel Cavalli, Francesco Rogliani, Paola Matera, Maria Gabriella |
author_sort | Cazzola, Mario |
collection | PubMed |
description | Asthma is a heterogeneous condition, but firm identification of heterogeneity-focused treatments is still lacking. Dividing patients into subgroups of asthma pheno-/endotypes based on combined clinical and cellular biological characteristics and linking them to targeted treatments could be a potentially useful approach to personalize therapy for better outcomes. Nonetheless, there are still many problems related to the identification and validation of asthma phenotypes and endotypes. Alternatively, a precision-medicine strategy for the management of patients with airways disease that is free from the traditional diagnostic labels and based on identifying "treatable traits" in each patient might be preferable. However, it would represent a quite unsophisticated approach because the definition of a treatable trait is too imprecise. In fact, there is still no understanding of the mechanisms underlying treatable traits that allow directing any targeted therapies against any particular treatable trait. Fortunately, in-depth identification of underlying molecular pathways to guide targeted treatment in individual patients is in progress thanks to the improvement in big data management obtained from ‘-omic’ sciences that is greatly increasing knowledge concerning asthma. |
format | Online Article Text |
id | pubmed-7956930 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer International Publishing |
record_format | MEDLINE/PubMed |
spelling | pubmed-79569302021-03-28 Treatable Mechanisms in Asthma Cazzola, Mario Ora, Josuel Cavalli, Francesco Rogliani, Paola Matera, Maria Gabriella Mol Diagn Ther Current Opinion Asthma is a heterogeneous condition, but firm identification of heterogeneity-focused treatments is still lacking. Dividing patients into subgroups of asthma pheno-/endotypes based on combined clinical and cellular biological characteristics and linking them to targeted treatments could be a potentially useful approach to personalize therapy for better outcomes. Nonetheless, there are still many problems related to the identification and validation of asthma phenotypes and endotypes. Alternatively, a precision-medicine strategy for the management of patients with airways disease that is free from the traditional diagnostic labels and based on identifying "treatable traits" in each patient might be preferable. However, it would represent a quite unsophisticated approach because the definition of a treatable trait is too imprecise. In fact, there is still no understanding of the mechanisms underlying treatable traits that allow directing any targeted therapies against any particular treatable trait. Fortunately, in-depth identification of underlying molecular pathways to guide targeted treatment in individual patients is in progress thanks to the improvement in big data management obtained from ‘-omic’ sciences that is greatly increasing knowledge concerning asthma. Springer International Publishing 2021-02-11 2021 /pmc/articles/PMC7956930/ /pubmed/33570719 http://dx.doi.org/10.1007/s40291-021-00514-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Current Opinion Cazzola, Mario Ora, Josuel Cavalli, Francesco Rogliani, Paola Matera, Maria Gabriella Treatable Mechanisms in Asthma |
title | Treatable Mechanisms in Asthma |
title_full | Treatable Mechanisms in Asthma |
title_fullStr | Treatable Mechanisms in Asthma |
title_full_unstemmed | Treatable Mechanisms in Asthma |
title_short | Treatable Mechanisms in Asthma |
title_sort | treatable mechanisms in asthma |
topic | Current Opinion |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7956930/ https://www.ncbi.nlm.nih.gov/pubmed/33570719 http://dx.doi.org/10.1007/s40291-021-00514-w |
work_keys_str_mv | AT cazzolamario treatablemechanismsinasthma AT orajosuel treatablemechanismsinasthma AT cavallifrancesco treatablemechanismsinasthma AT roglianipaola treatablemechanismsinasthma AT materamariagabriella treatablemechanismsinasthma |